ConvaTec Group PLC (CNVVY)
13.02
+0.84
(+6.93%)
USD |
OTCM |
May 03, 15:45
ConvaTec Group Max Drawdown (5Y): 60.93% for April 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
April 30, 2024 | 60.93% |
March 31, 2024 | 60.93% |
February 29, 2024 | 60.93% |
January 31, 2024 | 60.93% |
December 31, 2023 | 60.93% |
November 30, 2023 | 65.88% |
October 31, 2023 | 65.88% |
September 30, 2023 | 65.88% |
August 31, 2023 | 65.88% |
July 31, 2023 | 65.88% |
June 30, 2023 | 65.88% |
May 31, 2023 | 65.88% |
April 30, 2023 | 65.88% |
March 31, 2023 | 65.88% |
February 28, 2023 | 65.88% |
January 31, 2023 | 65.88% |
December 31, 2022 | 65.88% |
November 30, 2022 | 65.88% |
October 31, 2022 | 65.88% |
September 30, 2022 | 65.88% |
August 31, 2022 | 65.88% |
July 31, 2022 | 65.88% |
June 30, 2022 | 65.88% |
May 31, 2022 | 65.88% |
April 30, 2022 | 65.88% |
Date | Value |
---|---|
March 31, 2022 | 65.88% |
February 28, 2022 | 65.88% |
January 31, 2022 | 65.88% |
December 31, 2021 | 65.88% |
November 30, 2021 | 65.88% |
October 31, 2021 | 65.88% |
September 30, 2021 | 65.88% |
August 31, 2021 | 65.88% |
July 31, 2021 | 65.88% |
June 30, 2021 | 65.88% |
May 31, 2021 | 65.88% |
April 30, 2021 | 65.88% |
March 31, 2021 | 65.88% |
February 28, 2021 | 65.88% |
January 31, 2021 | 65.88% |
December 31, 2020 | 65.88% |
November 30, 2020 | 65.88% |
October 31, 2020 | 65.88% |
September 30, 2020 | 65.88% |
August 31, 2020 | 65.88% |
July 31, 2020 | 65.88% |
June 30, 2020 | 65.88% |
May 31, 2020 | 65.88% |
April 30, 2020 | 65.88% |
March 31, 2020 | 65.88% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
60.93%
Minimum
Dec 2023
65.88%
Maximum
May 2019
65.47%
Average
65.88%
Median
May 2019
Max Drawdown (5Y) Benchmarks
Adaptimmune Therapeutics PLC | 96.57% |
Biodexa Pharmaceuticals Plc | 100.00% |
Verona Pharma PLC | 89.71% |
NuCana PLC | 98.68% |
Autolus Therapeutics PLC | 96.58% |